Move Over, VIG: Why Yield-Hungry Investors Are Quietly Dumping Vanguard for This 3.3% Monster

The pitch for the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) has always sounded sensible. Own companies that raise their dividends every year, let compounding do the work. Then, collect a respectable yield while the equity grows.

However, the problem is VIG yields closer to 1.5% than anything an income investor would recognize. The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays roughly 3.3% and screens for dividend durability rather than dividend birthdays. For yield-hungry holders, that gap explains the steady drift from VIG into SCHD.

What VIG actually owns

VIG tracks the S&P U.S. Dividend Growers Index, which demands a 10-year streak of payout increases and then strips out the highest-yielding 25% of qualifying companies. That last screen is the part the brochure glosses over.

A company’s yield rises when its dividend grows faster than its share price, which is exactly the behavior a dividend-growth investor is supposed to reward. VIG punishes it by selling. What remains is a quality large-cap basket with a dividend veneer, tilted toward names that pay modest yields and plow the rest into buybacks and growth.

SCHD runs a different screen entirely. The Dow Jones U.S. Dividend 100 ranks companies on cash-flow-to-debt, return on equity, indicated yield, and five-year dividend growth, then weights roughly 100 holdings. Top 10 positions cluster between 3.97% and 4.26%, with heavy weights in pharma, energy, defense, telecom, consumer staples, and tobacco. Cash-rich, mature businesses unloved by anyone chasing AI.

The performance reality check

Over ten years, VIG returned 256% versus SCHD’s 238%, a gap that reflects VIG’s growthier tilt during the mega-cap tech run. So on pure long-term total return, VIG nudges ahead. The picture flips closer to the present. SCHD is up 26% over the past year against VIG’s 18%, and year-to-date SCHD has returned 18% while VIG sits at 7%. The value rotation has gone in SCHD’s favor.

The income gap is the part that should settle the debate for anyone buying these funds for cash. VIG’s last four quarterly payouts ran $0.83, $0.88, $0.86, and $0.87, roughly $3.45 in trailing payments against a $235 share price. SCHD’s trailing payments work out near $1.05 on a $32 share. A retiree drawing $40,000 a year from a dividend bucket reaches that number with a much smaller capital base in SCHD.

The tradeoffs SCHD holders inherit

1. Concentration in cyclicals and pharma. Energy and healthcare together are roughly a quarter of the fund. When crude cracks or drug-pricing legislation surfaces, SCHD absorbs it harder than a broad index would.
2. No AI exposure to speak of. The dividend screen excludes most of the names that drove market returns in 2024 and most of 2025. Wrong place for two years, right place more recently. Expect that cycle to keep turning.
3. Slower dividend growth than VIG long term. SCHD’s holdings already pay out generously, leaving less room for the kind of double-digit annual hikes VIG’s growthier names have delivered. You take more income now and accept a flatter raise trajectory.

Who actually belongs in which fund

SCHD fits the investor who wants the dividend check to fund spending or reinvest at a meaningful rate. A 0.06% expense ratio on $71.6 billion in assets means cost and liquidity are not the bottleneck. Willingness to underweight tech and overweight cyclicals is.

VIG fits a different person. Someone who wants a tilt toward profitable, shareholder-friendly large caps without paying for an actively managed quality fund, and who treats the dividend as a tax-inefficient afterthought rather than a paycheck. At 0.04% expenses, it is one of the cheapest ways to own a quality factor in equity form. The correct frame is to own VIG as a quality fund that happens to pay a dividend.